Published in Trends Pharmacol Sci on December 04, 2009
Translating dosage compensation to trisomy 21. Nature (2013) 1.75
Trisomy 21 and early brain development. Trends Neurosci (2011) 1.28
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun (2010) 1.14
Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome (2011) 1.08
The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech (2011) 1.05
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A (2011) 1.02
Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr (2010) 0.99
Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem (2011) 0.98
Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement (2014) 0.90
Brain phenotype of transgenic mice overexpressing cystathionine β-synthase. PLoS One (2012) 0.87
Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet (2013) 0.83
Overlapping trisomies for human chromosome 21 orthologs produce similar effects on skull and brain morphology of Dp(16)1Yey and Ts65Dn mice. Am J Med Genet A (2014) 0.83
Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS). BMC Med Genomics (2014) 0.79
Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome. PLoS One (2015) 0.78
Hippocampal circuit dysfunction in the Tc1 mouse model of Down syndrome. Nat Neurosci (2015) 0.78
Oxidative stress, thyroid dysfunction & Down syndrome. Indian J Med Res (2015) 0.77
The use of mouse models for understanding the biology of down syndrome and aging. Curr Gerontol Geriatr Res (2012) 0.77
"Down syndrome: an insight of the disease". J Biomed Sci (2015) 0.77
Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21. J Biomed Res (2010) 0.76
Disinhibition, an emerging pharmacology of learning and memory. F1000Res (2017) 0.75
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci (2017) 0.75
Down Syndrome: Current Status, Challenges and Future Perspectives. Int J Mol Cell Med (2016) 0.75
Integrated miRNA and mRNA expression profiling in fetal hippocampus with Down syndrome. J Biomed Sci (2016) 0.75
Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB. PLoS One (2011) 0.75
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
The DNA sequence of human chromosome 21. Nature (2000) 10.66
The specificities of protein kinase inhibitors: an update. Biochem J (2003) 7.76
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S A (1994) 3.61
An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science (2005) 3.61
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci (2004) 2.73
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A (2009) 2.36
Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001. MMWR Morb Mortal Wkly Rep (2006) 2.33
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A (1996) 2.32
Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science (2004) 2.19
The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci (2009) 2.12
The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev (2004) 2.12
The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev (2003) 2.03
Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet (2000) 1.96
Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene (2003) 1.93
Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet (2008) 1.90
Language development in Down syndrome: from the prelinguistic period to the acquisition of literacy. Ment Retard Dev Disabil Res Rev (2007) 1.87
Down syndrome--recent progress and future prospects. Hum Mol Genet (2009) 1.85
Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology (2004) 1.77
Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A (2001) 1.72
Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev (2007) 1.69
Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav (2003) 1.65
Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ (2008) 1.65
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet (2007) 1.57
Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet (2007) 1.57
Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. Proc Natl Acad Sci U S A (2006) 1.47
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci (2009) 1.46
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett (2008) 1.38
RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther (2008) 1.36
Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett (2005) 1.36
Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol (2000) 1.35
Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology (2007) 1.35
Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis (2004) 1.31
Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1. Mol Cell Neurosci (2002) 1.25
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol (2004) 1.24
A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet (2009) 1.20
Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn Mem (2008) 1.18
In two species, females exhibit superior working memory and inferior reference memory on the water radial-arm maze. Physiol Behav (2000) 1.13
Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol (2006) 1.12
Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev (2005) 1.12
Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res (2000) 1.11
Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One (2009) 1.10
Mouse models of cognitive disorders in trisomy 21: a review. Behav Genet (2006) 1.08
Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol (2004) 1.07
The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet (2006) 1.07
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol (2008) 1.06
Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex (2009) 0.99
On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog Neurobiol (2004) 0.98
GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci (2003) 0.96
Prevention of developmental delays in a Down syndrome mouse model. Obstet Gynecol (2008) 0.94
Promotion of neuronal plasticity by (-)-epigallocatechin-3-gallate. Neurochem Res (2007) 0.94
The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A (2009) 0.93
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci Lett (2005) 0.93
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des (2007) 0.92
Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav (2008) 0.92
The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol Behav (2002) 0.91
Down syndrome and the genes of human chromosome 21: current knowledge and future potentials. Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C., September 28-October 1, 2007. Cytogenet Genome Res (2008) 0.87
Object recognition memory is conserved in Ts1Cje, a mouse model of Down syndrome. Neurosci Lett (2007) 0.86
Vitamin E increases S100B-mediated microglial activation in an S100B-overexpressing mouse model of pathological aging. Glia (2008) 0.85
Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Am J Obstet Gynecol (2009) 0.85
Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav Brain Res (2007) 0.83